- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02053831
GalaFlex Mesh in Facelift
May 15, 2023 updated by: C. R. Bard
In this post market study a resorbable mesh (GalaFLEX) will be used to reinforce the lifted and imbricated SMAS along the suture lines and spread the load of the SMAS along a greater surface area.
GalaFLEX mesh is comprised of resorbable 4-hydroxybutyrate fibers.
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
15
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Ponte Vedra Beach, Florida, United States, 32083
- Ponte Vedra Plastic Surgery
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- The Few Institute for Aesthetic Plastic Surgery
-
Chicago, Illinois, United States, 60612
- Eye and Ear Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Primary Care Clinics
Description
Inclusion Criteria:
- Subject is able to understand the risks and benefits of participating in the study and must be willing to sign and date the Informed Consent Form for this study approved by the Institutional Review Board (IRB.)
- Be at least 21 years of age.
- Be willing and able to comply with the requirements of the protocol.
- Be willing to refrain from participating in any other investigational interventional study while enrolled in this study.
- Female subjects must have a negative pregnancy test within the last 24 hours timeline and have no intentions of becoming pregnant during participation in the study, or be sterilized.
Exclusion Criteria:
- Subject is unwilling or unable to give written consent to participate in the investigation or unable to comply with the requirements of the protocol.
- Subject has known severe allergies manifested by a history of anaphylaxis, or history or presence of severe multiple allergies.
- Subject has any serious skin disease, e.g., Eczema and psoriasis of the face, severe rosacea, scleroderma, local infections and severe acne.
- Subjects has diabetes, coagulation disorders, connective tissue disorders, lipodystrophy, or other serious systemic disease.
- Active herpes labialis
- Subject is infected with HIV and/or received or may receive immunosuppressive therapy over the course of the study (such as rheumatoid arthritis).
- Received any experimental drug or device within the previous three months.
- Known alcohol or drug abuser.
- Female subject who is pregnant or lactating or intending to become pregnant during the period of the study, or who would not use an adequate method of contraception (contraceptive pill, intra-uterine device) for the duration of the study.
- Possesses any psychological condition, or is under treatment for any condition which, in the opinion of the Investigator and/or consulting physicians(s),would constitute an unwarranted risk.
- Presents with severe jowling or severe cervical skin redundancy.
- Subject is currently a smoker or is a prior smoker who quit in the last 12 months.
- Active abscess or infection
- Currently involved with claims for, or is accepting, workers compensation
- Currently engaged in medical malpractice litigation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physician Satisfaction
Time Frame: 1 year
|
Investigator satisfaction will be judged by ease of product use, successful reinforcement, and total time for procedure to be completed.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Satisfaction
Time Frame: 1 year
|
Patient satisfaction will be judged by the difference between pre- and post-surgery answers to Quality of Life questionnaires.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Arikha Moses, Ph.D, Chief Scientific Officer, Founder
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
January 31, 2014
First Submitted That Met QC Criteria
January 31, 2014
First Posted (Estimate)
February 4, 2014
Study Record Updates
Last Update Posted (Actual)
May 16, 2023
Last Update Submitted That Met QC Criteria
May 15, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CP-1040
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Superficial Musculoaponeurotic System (SMAS) Procedure
-
Shaheen AlaneeMerck Sharp & Dohme LLCUnknownEndoscopic Surgical Procedure | High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma | Transitional Epithelial CellsUnited States
-
Chinese University of Hong KongCompletedSuperficial Esophageal Neoplasia
-
Rennes University HospitalCompletedPancreaticoduodenectomy | Digestive System Surgical ProcedureFrance
-
The Guthrie ClinicWithdrawnCaffeinated Gum to Prevent Post-Operative Ileus: A Prospective, Randomized, Placebo-controlled TrialC.Surgical Procedure; Digestive SystemUnited States
-
Shanghai Chest HospitalNot yet recruitingSurgical Procedure, UnspecifiedChina
-
Thomas SteffenCompletedDiagnosis-Related Groups | Healthcare Common Procedure Coding SystemSwitzerland
-
Universidad Abierta InteramericanaUnknownSuperficial Radial Nerve LesionArgentina
-
University of ZurichCompletedSuperficial Digital Flexor TendonitisSwitzerland
-
Johannes Gutenberg University MainzUnknownSurgical Procedure, UnspecifiedGermany